Castle Biosciences (NASDAQ:CSTL) Insider Sells $137,640.10 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 6,214 shares of the firm’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $22.15, for a total transaction of $137,640.10. Following the completion of the transaction, the insider directly owned 21,479 shares in the company, valued at $475,759.85. This trade represents a 22.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Down 2.6%

Castle Biosciences stock opened at $18.15 on Thursday. Castle Biosciences, Inc. has a 1-year low of $14.59 and a 1-year high of $44.28. The firm has a market capitalization of $550.49 million, a price-to-earnings ratio of -41.25 and a beta of 1.11. The firm’s fifty day moving average price is $24.52 and its two-hundred day moving average price is $32.02. The company has a current ratio of 6.75, a quick ratio of 6.53 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.49). The business had revenue of $84.23 million during the quarter, compared to the consensus estimate of $79.23 million. Castle Biosciences had a negative net margin of 3.78% and a negative return on equity of 2.77%. On average, equities research analysts predict that Castle Biosciences, Inc. will post -1.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Castle Biosciences

Institutional investors have recently made changes to their positions in the stock. Federated Hermes Inc. purchased a new stake in shares of Castle Biosciences in the 4th quarter valued at $26,000. Farther Finance Advisors LLC raised its holdings in Castle Biosciences by 139,100.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock valued at $32,000 after buying an additional 1,391 shares during the last quarter. State of Alaska Department of Revenue bought a new stake in Castle Biosciences during the 3rd quarter valued at $35,000. Kemnay Advisory Services Inc. bought a new stake in Castle Biosciences during the 4th quarter valued at $35,000. Finally, CWM LLC raised its holdings in Castle Biosciences by 80.6% during the 3rd quarter. CWM LLC now owns 1,911 shares of the company’s stock valued at $44,000 after buying an additional 853 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Castle Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. KeyCorp reissued an “overweight” rating and issued a $50.00 price target on shares of Castle Biosciences in a research report on Thursday, January 29th. Weiss Ratings lowered shares of Castle Biosciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, May 7th. BTIG Research lowered their price target on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Zacks Research raised shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Castle Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $44.57.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.